Poo JL, Muñoz LE

Idioma: Ingles.
Referencias bibliográficas: 4
Paginas: 845-846
Archivo PDF: 47.49 Kb.

RESUMEN

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Flores-Contreras L, Sandoval-Rodríguez A, Mena-Enriquez M, Lucano-Landeros S, Arellano-Olivera I, Alvarez- Alvarez A, Sánchez-Parada G, et al. Treatment with Poo JL, et al. , 2014; 13 (6): 845-846 846 pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterology 2014; 14: 131-41.

2. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. The Journal of Clinical Investigation 2013; 123: 1887-901.

3. Xaubet A, Serrano-Mollar A, Ancochea J. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert opinion on pharmacotherapy 2014: 1-7.

4. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-7.